Several potential jurors at the federal securities fraud trial of Martin ‘Pharma Bro’ Shkreli were excused on Monday after telling the judge they couldn’t be impartial toward the flamboyant former pharmaceutical CEO because of his notoriety for raising the cost of a life-saving drug 5,000 percent. Though Shkreli’s notoriety came from Daraprim, a drug used to treat toxoplasmosis and HIV, the federal securities fraud case is unrelated.